Analyses related to the development of DSM-5 criteria for substance use related disorders: 2. Proposed DSM-5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients.
about
The Classification of Substance Use Disorders: Historical, Contextual, and Conceptual ConsiderationsChildhood maltreatment, 9/11 exposure, and latent dimensions of psychopathology: A test of stress sensitizationDSM-5 criteria for substance use disorders: recommendations and rationaleConcordance between DSM-5 and DSM-IV nicotine, alcohol, and cannabis use disorder diagnoses among pediatric patients.Craving as an alcohol use disorder symptom in DSM-5: an empirical examination in a treatment-seeking sample.Alcohol consumption mediates the relationship between ADH1B and DSM-IV alcohol use disorder and criteriaParental alcohol history differentially predicts offspring disorders in distinct subgroups in Israel.A pilot study of brief heart rate variability biofeedback to reduce craving in young adult men receiving inpatient treatment for substance use disordersAcute immunomodulatory effects of binge alcohol ingestionThe Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): procedural validity of substance use disorders modules through clinical re-appraisal in a general population sample.Does DSM-5 nomenclature for inhalant use disorder improve upon DSM-IV?Plasma concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders: relationship to psychiatric comorbidityCo-occurrence of alcohol, drug use, DSM-5 alcohol use disorder, and symptoms of drug use disorder on both sides of the U.S.-Mexico border.Nosologic Comparisons of DSM-IV and DSM-5 Alcohol and Drug Use Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.Inter-observer reliability of DSM-5 substance use disordersOpioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates.Limits of Current Approaches to Diagnosis Severity Based on Criterion Counts: An Example with DSM-5 Alcohol Use Disorder.Determining optimal diagnostic criteria through chronicity and comorbidity.Assessment of a modified DSM-5 diagnosis of alcohol use disorder in a genetically informative population.Meta-analysis of DSM alcohol use disorder criteria severities: structural consistency is only 'skin deep'.Differences in childhood physical abuse reporting and the association between CPA and alcohol use disorder in European American and African American womenPrevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sampleValidity of proposed DSM-5 diagnostic criteria for nicotine use disorder: results from 734 Israeli lifetime smokers.Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: Substance abusers and others in the general population.Commonalities and Differences Across Substance Use Disorders: Phenomenological and Epidemiological AspectsItem response theory analyses of DSM-IV and DSM-5 stimulant use disorder criteria in an American Indian community sample.Heart rate variability biofeedback: Theoretical basis, delivery, and its potential for the treatment of substance use disorders.DSM-5 cannabis use disorder: a phenotypic and genomic perspective.Trauma exposure, posttraumatic stress disorder and risk for alcohol, nicotine, and marijuana dependence in Israel.Comparing factor, class, and mixture models of cannabis initiation and DSM cannabis use disorder criteria, including craving, in the Brisbane longitudinal twin study.Childhood adversity moderates the effect of ADH1B on risk for alcohol-related phenotypes in Jewish Israeli drinkers.The Puzzling Unidimensionality of DSM-5 Substance Use Disorder Diagnoses.Association of Specific Traumatic Experiences With Alcohol Initiation and Transitions to Problem Use in European American and African American Women.Item Response Theory Analysis to Assess Dimensionality of Substance Use Disorder Abuse and Dependence Symptoms.Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity.Craving as a DSM-5 Symptom of Alcohol Use Disorder in Non-Treatment Seekers.Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity.Regulating Cannabis Manufacturing: Applying Public Health Best Practices from Tobacco Control.DSM-IV and DSM-5 alcohol use disorder among young Swiss men.An assessment of the compatibility of DSM-IV and proposed DSM-5 criteria in the diagnosis of cannabis use disorders.
P2860
Q26739919-38C3DBCD-F7D9-44CE-866C-6E98D9F178A2Q28396187-89EED4B1-D9EE-4306-AA66-FEACB798AB40Q30544314-1E7AFEC1-9A8E-429C-87D8-F7E06A6AC570Q33806385-31CEBD60-5660-474C-897B-804C82021811Q33926257-C96C267E-4EDB-40C8-8591-32FB7A7981C2Q33940968-6190234C-16C9-4C3E-A328-3112BD066877Q34168063-14B32ED3-2A10-4C4B-B258-2AAC19A6FF0EQ34457660-A14D8BD4-8DC3-4426-AE81-FC547EA49043Q35039859-71D2125A-48CF-474A-B452-C49481DDC1CBQ35088286-512AB7B0-0FF1-4210-9491-945BC6C9F358Q35097229-1C57A8EE-5C7A-4455-B3D8-E7BC5531542EQ35143914-C5F6A6AF-4505-4C65-8299-5D142F7170C4Q35256192-A76EE0B5-FEAF-42CE-B986-10D7F16441A9Q35632872-C7620771-96AB-40FC-9956-F9D55C5A4CA5Q35875576-F041A541-BCBE-4FF5-B269-91816E2CCDD8Q35994226-7998CA6F-B68E-4138-9FE7-F6E6DF538213Q36467743-796E1E14-6003-4F55-812B-5A568C7FC20DQ36526445-019A37E0-CC0D-4887-880F-7BA84BB492F0Q36650694-EC450B96-6A81-4F3F-8F98-AE301BDCB642Q36972775-65B5F650-DB96-4C71-8827-979A74956FDBQ37024762-E687E902-D211-4710-965B-AD45616051A3Q37055258-E4C20DF4-B07F-4364-9B67-498BB5B7FD5EQ37156770-B9012A19-CC2F-4DA1-A662-6B357F1C683DQ37384505-3668B569-8CA3-4E6F-911C-FDCA30CC47ECQ37395047-D21722E8-632E-4B81-9E04-B372F8D44436Q37561266-F9E6B9FE-44EF-4476-A16C-D8B66BEFADA4Q37574233-125CAF31-6AA8-4C95-B383-E7CF355222C3Q37619195-2501D110-C4C0-4531-AC0A-B48EF44F57BEQ37662681-A8C242CA-75D3-4DF5-9A4E-53DFD81CB4FCQ37718824-DCD8F20A-5A69-4FF3-B4F8-BE8CB00494DAQ37722731-A0D415EA-A761-4F70-B01D-3783F42D2F12Q38170108-A3A8BD88-A263-4B4A-9E1A-35A0517AF123Q39363219-5FA8FE78-9320-456B-8FDA-42399872F27BQ41714127-9935BF11-05BB-4A78-842A-C9B13E3743D5Q45909094-459153C9-687A-4B10-8B24-75F98F6E4B3AQ46311527-651D5848-7F5E-4048-9FD7-DCFA071DF2E1Q46662676-E10732D9-C072-4456-93D8-4EB1EA50A606Q50041116-383A8543-E610-4A87-A080-E4AE21A98B50Q50612929-7EEE1F22-32B7-4200-B20F-7B0BAAE835DBQ50745327-2B5D8DE7-4DB6-4263-BBA8-368D886474B2
P2860
Analyses related to the development of DSM-5 criteria for substance use related disorders: 2. Proposed DSM-5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 October 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Analyses related to the develo ...... 663 substance abuse patients.
@en
Analyses related to the develo ...... 663 substance abuse patients.
@nl
type
label
Analyses related to the develo ...... 663 substance abuse patients.
@en
Analyses related to the develo ...... 663 substance abuse patients.
@nl
prefLabel
Analyses related to the develo ...... 663 substance abuse patients.
@en
Analyses related to the develo ...... 663 substance abuse patients.
@nl
P2093
P2860
P1476
Analyses related to the develo ...... 663 substance abuse patients.
@en
P2093
Cheryl Beseler
Jung Yeon Park
Melanie M Wall
Miriam C Fenton
P2860
P356
10.1016/J.DRUGALCDEP.2011.09.005
P577
2011-10-02T00:00:00Z